MEDIA CENTER2018-11-19T17:53:23-06:00

Latest news from Rapha Capital Management & our portfolio companies

Poseida Therapeutics
Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma
Efficacy and safety continue to be a major advantage, with a very high response rate, no dose limiting toxicities and only a single incidence of suspected cytokine release syndrome. P-BCMA-101 clinical data as well as preclinical data from MUC1C and PSMA solid tumor programs and BCMA allogeneic program presented at the CAR-TCR Summit
September 5, 2018

Numat Technologies
NuMat Technologies Closes $12.4M Funding Round to Accelerate Commercialization of Molecularly Engineered Products
April 26, 2018

NuMat Technologies, Inc
Versum Materials and NuMat Technologies to Commercialize Next-Generation Adsorbent Technology for Delivery of Dopant Gases

The ION-X® technology platform enables IC manufacturers to meet increasingly demanding performance requirements

  • Drives participation in profitable growth market critical for semiconductor manufacturing process
  • Leverages Versum Materials’ global infrastructure and franchise
  • Creates value for customers by enabling new and differentiated technology

July 17, 2017

Go to Top